Why do Pharma Ecosystems Require Continuity? The Case of AstraZeneca
The coronavirus crisis has brought together engineering firms (including Formula One rivals), universities, the NHS, pharmaceutical firms, start-ups and government regulators to address the twin challenges of rapidly manufacturing more ventilators and coming up with a new vaccine. In times of emergency, such ecosystems are crucial for innovation. Business ecosystems develop slowly over time based on trust relationships, but they are vulnerable to disruption.
In this session, Hossam Zeitoun will discuss the threat of disruption using the takeover battle between Pfizer and AstraZeneca, offering guidelines for managing stakeholders in a dynamic ecosystem.
Hossam Zeitoun’s principal research interests are behavioural science, strategic management and corporate governance. He applies an interdisciplinary approach using organisational, psychological and economic perspectives.